LOGO
LOGO

FDA Calendar - Capricor Therapeutics, Inc.

Company Name Capricor Therapeutics, Inc.
CAPR
Drug Name Deramiocel (resubmitted BLA)
Event Name FDA decision on Deramiocel to treat Duchenne muscular dystrophy cardiomyopathy
Event Date 08/22/2026
Outcome Date
Outcome Pending
Drug Status FDA declined to approve Deramiocel for Duchenne Muscular Dystrophy on July 11, 2025.
Rival Drugs If approved, Deramiocel would be the first therapy to treat Duchenne muscular dystrophy cardiomyopathy
Market Potential
Other Approvals
News
Return to FDA Calendar
RELATED NEWS (Capricor Therapeutics, Inc.)
Editors Pick
spacexipov2 12062026 lt

SpaceX Raises $75 Bln In IPO, Turning Musk First Trillionaire

June 12, 2026 08:31 ET
adobe 12062026 lt

Adobe Stock Drops As CFO Dan Durn Resigns Overshadowing Higher Q2 Results, Outlook Upgrade

June 12, 2026 05:25 ET
oracle 11062026 lt

Oracle Q4 Results Strong, Outlook Positive, But Stock Drops On Plan To Raise $20 Bln More

June 11, 2026 04:57 ET
gsk 09062026 lt

Nuvalent Stock Climbs 39% On $10.6 Bln Takeover Deal With GSK

June 09, 2026 08:05 ET
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap